Sonali Smith to Antineoplastic Agents
This is a "connection" page, showing publications Sonali Smith has written about Antineoplastic Agents.
Connection Strength
1.079
-
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr; 4(4):e176-e182.
Score: 0.265
-
New drugs for the treatment of non-Hodgkin lymphomas. Chin Clin Oncol. 2015 Mar; 4(1):14.
Score: 0.230
-
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul; 54(7):1405-10.
Score: 0.199
-
Targeting mTOR in mantle cell lymphoma: current and future directions. Best Pract Res Clin Haematol. 2012 Jun; 25(2):175-83.
Score: 0.190
-
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
Score: 0.169
-
Nonmyeloablative transplantation for lymphoma. Curr Treat Options Oncol. 2003 Aug; 4(4):261-8.
Score: 0.026